{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:54:14Z","timestamp":1793962454609,"version":"4.8.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,9]]},"DOI":"10.1097\/01.crd.0000086892.07437.05","type":"journal-article","created":{"date-parts":[[2003,11,11]],"date-time":"2003-11-11T10:46:39Z","timestamp":1068547599000},"page":"262-274","source":"Crossref","is-referenced-by-count":22,"title":["Diabetes and Heart Disease"],"prefix":"10.1097","volume":"11","author":[{"given":"Amale A.","family":"Lteif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieren J.","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210203","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.2337\/diacare.21.9.1414","article-title":"Global burden of diabetes, 1995\u20132025: prevalence, numerical estimates, and projections","volume":"21","author":"King","year":"1998","journal-title":"Diabetes Care"},{"key":"R2-7-20210203","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2337\/diacare.21.4.518","article-title":"Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988\u20131994","volume":"21","author":"Harris","year":"1998","journal-title":"Diabetes Care"},{"key":"R3-7-20210203","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1515\/JPEM.2002.15.S2.737","article-title":"Type 2 diabetes mellitus in children and youth: a new epidemic","volume":"15","author":"Kaufman","year":"2002","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R4-7-20210203","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/diacare.21.1.69","article-title":"Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group","volume":"21","author":"Miettinen","year":"1998","journal-title":"Diabetes Care"},{"key":"R5-7-20210203","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Banting lecture 1988. Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes"},{"key":"R6-7-20210203","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetes Med"},{"key":"R7-7-20210203","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2337\/diacare.24.4.683","article-title":"Cardiovascular morbidity and mortality associated with the metabolic syndrome","volume":"24","author":"Isomaa","year":"2001","journal-title":"Diabetes Care"},{"key":"R8-7-20210203","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R9-7-20210203","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/01.CIR.97.10.996","article-title":"Insulin and risk of cardiovascular disease: a meta-analysis","volume":"97","author":"Ruige","year":"1998","journal-title":"Circulation"},{"key":"R10-7-20210203","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1210\/jcem.83.8.5005","article-title":"Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease","volume":"83","author":"Yip","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-7-20210203","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1046\/j.1464-5491.1999.00075.x","article-title":"The British Diabetic Association Cohort Study, I: all-cause mortality in patients with insulin-treated diabetes mellitus","volume":"16","author":"Laing","year":"1999","journal-title":"Diabetes Med"},{"key":"R12-7-20210203","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2337\/diab.41.2.202","article-title":"Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study","volume":"41","author":"Singer","year":"1992","journal-title":"Diabetes"},{"key":"R13-7-20210203","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2337\/diacare.22.2.233","article-title":"The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12. 4 years","volume":"22","author":"Coutinho","year":"1999","journal-title":"Diabetes Care"},{"key":"R14-7-20210203","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.322.7277.15","article-title":"Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk)","volume":"322","author":"Khaw","year":"2001","journal-title":"BMJ"},{"key":"R15-7-20210203","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2337\/diacare.2.2.120","article-title":"Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study","volume":"2","author":"Kannel","year":"1979","journal-title":"Diabetes Care"},{"key":"R16-7-20210203","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"key":"R17-7-20210203","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jama.1991.03460050081025","article-title":"Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study","volume":"265","author":"Barrett-Connor","year":"1991","journal-title":"JAMA"},{"key":"R18-7-20210203","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"R19-7-20210203","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"key":"R20-7-20210203","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"R21-7-20210203","first-page":"B21","article-title":"Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients","volume":"23","author":"Shichiri","year":"2000","journal-title":"Diabetes Care"},{"key":"R22-7-20210203","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/archinte.1997.00440230053007","article-title":"Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes","volume":"157","author":"Abraira","year":"1997","journal-title":"Arch Intern Med"},{"key":"R23-7-20210203","first-page":"A74","article-title":"The Diabetes Control and Complications Trial (DCCT)\/Epidemiology of Diabetes Intervention and Complications (EDIC) Study Group","volume":"50","author":"Molitch","year":"2001","journal-title":"Diabetes"},{"key":"R24-7-20210203","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"R25-7-20210203","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0735-1097(95)00126-K","article-title":"Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year","volume":"26","author":"Malmberg","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"R26-7-20210203","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1161\/01.CIR.99.20.2626","article-title":"Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study","volume":"99","author":"Malmberg","year":"1999","journal-title":"Circulation"},{"key":"R27-7-20210203","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"R28-7-20210203","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","article-title":"Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study","volume":"321","author":"Adler","year":"2000","journal-title":"BMJ"},{"key":"R29-7-20210203","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"R30-7-20210203","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/archinte.1997.00440420033005","article-title":"The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure","volume":"157","year":"1997","journal-title":"Arch Intern Med"},{"key":"R31-7-20210203","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R32-7-20210203","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"R33-7-20210203","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"R34-7-20210203","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"R35-7-20210203","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"R36-7-20210203","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"R37-7-20210203","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet"},{"key":"R38-7-20210203","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","article-title":"The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension","volume":"338","author":"Estacio","year":"1998","journal-title":"N Engl J Med"},{"key":"R39-7-20210203","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/diacare.21.4.597","article-title":"Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM","volume":"21","author":"Tatti","year":"1998","journal-title":"Diabetes Care"},{"key":"R40-7-20210203","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2337\/diacare.24.4.654","article-title":"Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"24","author":"Barzilay","year":"2001","journal-title":"Diabetes Care"},{"key":"R41-7-20210203","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"R42-7-20210203","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/diacare.20.4.614","article-title":"Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)","volume":"20","author":"Pyorala","year":"1997","journal-title":"Diabetes Care"},{"key":"R43-7-20210203","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/01.CIR.98.23.2513","article-title":"Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators","volume":"98","author":"Goldberg","year":"1998","journal-title":"Circulation"},{"key":"R44-7-20210203","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"R45-7-20210203","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"R46-7-20210203","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"R47-7-20210203","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"R48-7-20210203","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2337\/diacare.14.4.308","article-title":"Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM","volume":"14","author":"Hanefeld","year":"1991","journal-title":"Diabetes Care"},{"key":"R49-7-20210203","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.2337\/diabetes.48.6.1289","article-title":"Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial","volume":"48","author":"Hoogwerf","year":"1999","journal-title":"Diabetes"},{"key":"R50-7-20210203","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2337\/diacare.21.4.641","article-title":"Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary\u2019s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study","volume":"21","author":"Elkeles","year":"1998","journal-title":"Diabetes Care"},{"key":"R51-7-20210203","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"R52-7-20210203","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"R53-7-20210203","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1464-5491.2002.00643.x","article-title":"Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes","volume":"19","author":"Colhoun","year":"2002","journal-title":"Diabetes Med"},{"key":"R54-7-20210203","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists\u2019 Collaboration","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"R55-7-20210203","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198907203210301","article-title":"Final report on the aspirin component of the ongoing Physicians\u2019 Health Study. Steering Committee of the Physicians\u2019 Health Study Research Group","volume":"321","year":"1989","journal-title":"N Engl J Med"},{"key":"R56-7-20210203","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2337\/diacare.20.4.537","article-title":"Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study","volume":"20","author":"Pan","year":"1997","journal-title":"Diabetes Care"},{"key":"R57-7-20210203","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"N Engl J Med"},{"key":"R58-7-20210203","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"R59-7-20210203","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.2337\/diabetes.51.9.2796","article-title":"Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women","volume":"51","author":"Buchanan","year":"2002","journal-title":"Diabetes"},{"key":"R60-7-20210203","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"key":"R61-7-20210203","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0197-2456(01)00165-9","article-title":"Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience","volume":"22","author":"Torgerson","year":"2001","journal-title":"Control Clin Trials"},{"key":"R62-7-20210203","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.286.15.1882","article-title":"Ramipril and the development of diabetes","volume":"286","author":"Yusuf","year":"2001","journal-title":"JAMA"},{"key":"R63-7-20210203","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"R64-7-20210203","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.103.3.357","article-title":"Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study","volume":"103","author":"Freeman","year":"2001","journal-title":"Circulation"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003086-200306000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T04:28:35Z","timestamp":1618028915000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045415-200309000-00007"}},"subtitle":["An Evidence-Driven Guide to Risk Factors Management in Diabetes"],"short-title":[],"issued":{"date-parts":[[2003,9]]},"references-count":64,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003]]}},"URL":"https:\/\/doi.org\/10.1097\/01.crd.0000086892.07437.05","relation":{},"ISSN":["1061-5377"],"issn-type":[{"value":"1061-5377","type":"print"}],"subject":[],"published":{"date-parts":[[2003,9]]}}}